Body fat chemicals in postmenopausal women with breast cancer and excess weight
Measures bioactive lipids in postmenopausal women, with and without breast cancer or obesity.
Plain-language title generated from the registry record
Registry title: Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases
Key facts
- Where
- Pamplona, SpainSee the 2 sites
Where in Spain
- Center for Nutrition ResearchPamplona, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Clinica Universidad de Navarra, Universidad de Navarra
- Trial code
- NCT07447440
- Record updated
- 11 March 2026
- Original description
The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight/obesity.Read full original descriptionShow less
Unraveling the Role of Pro-Resolving Lipid Mediators of Inflammation and Their Receptors in Obesity-Associated Diseases: New Therapeutic Approaches for Maresin 1 (RESOLBE)
The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight/obesity.
Specific objectives are:
* To analyse anthropometric and body composition changes. * To evaluate physical activity level. * To determine dietary profile. * To determine the adherence to Mediterranean dietary pattern. * To assess the quality of life. * To determine levels of specialized pro-resolving lipid mediators
The target sample size is 60 subjects. Participants will be allocated in four groups:
* Group 1: Postmenopausal healthy women with overweight/obesity (n=15) * Group 2: Postmenopausal healthy women with normoweight (n=15) * Group 3: Postmenopausal women with breast cancer and overweight/obesity (n=15) * Group 4: Postmenopausal women with breast cancer and normoweight (n=15)
Inclusion: Postmenopause (al least 1 year); Normoweight or overweight/obesity; No personal history of cancer; Stable weight over the last 3 months (±5%); Willing to sign the informed consent and comply with all study procedures; Postmenopause (at least 1 year); Normoweight or overweight/obesity; Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment; Willing to sign the informed consent and comply with all study procedures.
Exclusion: Current weight loss treatment (diet, supplementation, surgery, others...); Bariatric surgery; Surgical interventions resulting in permanent sequelae of the gastrointestinal tract; Personal history of cancer; Diabetes treatment and hormone replacement therapy; Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc; Liver disease, except for non-alcoholic fatty liver disease; Cognitive and/or psychiatric impairment; Poor compliance or difficulty following study procedures; BREAST CANCER PARTICIPANTS:; Luminal subtype breast cancer stages over than II or other type of breast cancer; No stable pharmacological treatment for at least 3 months; High alcohol intake, more than 14 units per week for women and 20 units per week for men; Require preoperative treatment.
HEALTHY PARTICIPANTS:.